Elite in Acute Myeloid Leukemia (AML)
Check Dr. Eytan M. Stein's experience treating your condition:
About Dr. Eytan M. Stein

Eytan Stein is a Hematologist Oncology expert in New York, New York. Stein has been practicing medicine for over 16 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in New York. Stein is currently accepting new patients.

His clinical research consists of co-authoring 133 peer reviewed articles and participating in 11 clinical trials in the past 15 years. In particular, he has co-authored 93 articles and participated in 9 clinical trials in the study of Acute Myeloid Leukemia (AML).


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Eytan M. Stein it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
1275 York Ave, New York, NY 10065
Background & Education
Graduate Institution
Northwestern University Feinberg Medical School, 2007
Hematology Oncology
Internal Medicine in NY
Hospital Affiliations
Memorial Sloan Kettering Cancer Center
Riverview Medical Center
Shore Medical Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With RARA-positive, Previously Untreated AML Who Are Ineligible for Standard Induction Therapy
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Phase II Clinical Trial of E7820 for Patients With Relapsed/Refractory Myeloid Malignancies With Mutations in Splicing Factor Genes.
A Pilot Study of Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
View 3 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors